Marc Frahm
Stock Analyst at TD Cowen
(0.26)
# 3,581
Out of 4,667 analysts
15
Total ratings
18.18%
Success rate
-22.85%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Marc Frahm
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TBPH Theravance Biopharma | Maintains: Hold | $10 → $9 | $9.90 | -9.04% | 3 | Aug 6, 2024 | |
| INCY Incyte | Maintains: Buy | $88 → $80 | $70.18 | +13.99% | 3 | May 1, 2024 | |
| SANA Sana Biotechnology | Initiates: Market Perform | n/a | $2.37 | - | 1 | Aug 14, 2023 | |
| CGEM Cullinan Therapeutics | Initiates: Outperform | n/a | $12.25 | - | 1 | Jun 15, 2023 | |
| XLO Xilio Therapeutics | Initiates: Outperform | n/a | $0.90 | - | 1 | Nov 16, 2021 | |
| NUVL Nuvalent | Initiates: Outperform | n/a | $92.53 | - | 1 | Aug 23, 2021 | |
| ELEV Elevation Oncology | Initiates: Outperform | n/a | $0.61 | - | 1 | Jul 20, 2021 | |
| JANX Janux Therapeutics | Initiates: Outperform | n/a | $47.47 | - | 1 | Jul 6, 2021 | |
| DAWN Day One Biopharmaceuticals | Initiates: Outperform | n/a | $13.40 | - | 1 | Jun 21, 2021 | |
| INZY Inozyme Pharma | Initiates: Outperform | n/a | $2.66 | - | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.36 | - | 1 | Feb 24, 2020 |
Theravance Biopharma
Aug 6, 2024
Maintains: Hold
Price Target: $10 → $9
Current: $9.90
Upside: -9.04%
Incyte
May 1, 2024
Maintains: Buy
Price Target: $88 → $80
Current: $70.18
Upside: +13.99%
Sana Biotechnology
Aug 14, 2023
Initiates: Market Perform
Price Target: n/a
Current: $2.37
Upside: -
Cullinan Therapeutics
Jun 15, 2023
Initiates: Outperform
Price Target: n/a
Current: $12.25
Upside: -
Xilio Therapeutics
Nov 16, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.90
Upside: -
Nuvalent
Aug 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $92.53
Upside: -
Elevation Oncology
Jul 20, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.61
Upside: -
Janux Therapeutics
Jul 6, 2021
Initiates: Outperform
Price Target: n/a
Current: $47.47
Upside: -
Day One Biopharmaceuticals
Jun 21, 2021
Initiates: Outperform
Price Target: n/a
Current: $13.40
Upside: -
Inozyme Pharma
Aug 18, 2020
Initiates: Outperform
Price Target: n/a
Current: $2.66
Upside: -
Feb 24, 2020
Initiates: Outperform
Price Target: n/a
Current: $2.36
Upside: -